A Phase I Study of the DNA-PK Inhibitor Peposertib in Combination with Radiotherapy with or without Cisplatin in Patients with Advanced Head and Neck Tumors

CONCLUSION: Peposertib in combination with palliative RT was well-tolerated up to doses of 200 mg QD as tablet with each RT fraction. When combined with RT and cisplatin, a tolerable peposertib dose yielded insufficient …